None of the comparative studies of robotic radical nephrectomies (RRN) and laparoscopic radical nephrectomies (LRN) has shown benefit of RRN over LRN. Why then are so many minimally invasive RNs performed this way?
Two recent studies highlight the increasing use of robotic radical nephrectomy in the United States. Using the Nationwide Inpatient Sample, Weinberg and associates found that the proportion of radical nephrectomies (RNs) performed robotically in the U.S. increased from 2% to 8% from 2008 to 2010 (see "Use of robotic RN rising, despite unclear advantages"). Yang et al, using the same database, determined that among the minimally invasive RNs performed in the U.S. from 2009 to 2011, 71% were laparoscopic (LRN) and 29% were robotic (RRN) (J Urol 2014; 191:e58-59). They found no differences in comorbidities, perioperative complications, or mortality between the two procedures. RRN was associated with an $11,267 (~29%) increase in charges.
None of the comparative studies of RRN and LRN has shown benefit of RRN over LRN. Why then are so many minimally invasive RNs performed this way? There are many possible reasons: to gain experience with robotic surgery, to increase robot utilization, to market the procedure, and others. Unfortunately, none of these reasons makes up for the high cost of RRN, which includes not only the cost of the robot and limited-use instruments but also the expense of the necessary experienced bedside assistant.
An additional motivation is that some surgeons may not be facile with standard LRN and, wanting to provide a minimally invasive alternative, feel that they need the robot to provide that. In my opinion, this justification applies to such procedures as prostatectomy, radical cystectomy, partial nephrectomy, and pyeloplasty-reconstructive procedures that take advantage of the robot’s capabilities. In the case of RN, however, there is a mature and robust experience with hand-assisted LRN, which has been shown repeatedly to provide results similar to standard LRN but with a much shorter learning curve. If minimally invasive RN is desired and standard LRN is not within the skill set, then I suggest hand-assisted LRN over RRN.
RRN is a reasonable choice for RN associated with vena caval tumor thrombectomy, to facilitate single-site surgery, and in the unusual case of a renal cancer patient who is concerned about the extra few centimeters of incision for hand-assisted LRN (if standard LRN is not an option). Beyond that, frankly, RRN does not make any sense.UT
Subscribe to Urology Times to get monthly news from the leading news source for urologists.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists
March 31st 2021“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.